TY  - JOUR
T1  - Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies Standard of care
A1  - Cavalieri, Stefano
A1  - Filippini, Daria Maria
A1  - Ottini, Arianna
A1  - Bergamini, Cristiana
A1  - Resteghini, Carlo
A1  - Colombo, Elena
A1  - Lombardo, Roberta
A1  - Nuzzolese, Imperia
A1  - Alfieri, Salvatore
A1  - Licitra, Lisa
A1  - Locati, Laura D
Y1  - 2021///
KW  - Head and neck cancer
KW  - immune checkpoint inhibitors
KW  - rare cancer
JF  - Exploration of Targeted Anti-tumor Therapy
VL  - 2
IS  - 6
SP  - 522
EP  - 542
DO  - 10.37349/etat.2021.00062
UR  - https://www.explorationpub.com/Journals/etat/Article/100262
N2  - The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In recent years, the deeper and increasing knowledge on the genomic landscape and the upcoming new data on immunotherapy enacted by HNSCCs have led to successful therapeutic targeting of the immune system. Immune checkpoint inhibitors (ICIs) have changed state of the art in R/M patients and could have a potential role even in early disease. The purpose of this work is to summarize the role of immunotherapy for R/M HNSCC in clinical practice, with insights about future perspectives. Updated immunotherapy results in other R/M head and neck cancers such as thyroid, salivary glands, nasopharynx, sinonasal cancers, and nuclear protein in testis (NUT) are presented.
ER  -